中性粒细胞百分比与白蛋白比值(NPAR)在儿童肺炎支原体肺炎严重程度及并发症的价值
The Value of Neutrophil Percentage to Albumin Ratio (NPAR) in Assessing Severity and Complications of Mycoplasma Pneumoniae Pneumonia in Children
摘要: 目的:探讨中性粒细胞百分比与白蛋白比值(neutrophil percentage to albumin ratio, NPAR)在儿童肺炎支原体肺炎(MPP)严重程度及并发症的关系,并评估其临床应用价值。方法:回顾性分析2023年1月至2024年6月安徽医科大学第一附属医院儿科的290例MPP患儿的临床资料,根据病情严重程度分为重症组(SMPP,82例)和非重症组(NSMPP,208例)。比较两组临床特征及实验室指标,构建SMPP的logistic回归模型分析相关危险因素,并分别建立含CRP与不含CRP的嵌套模型以评估NPAR的增量效应。以NPAR的中位数将患儿分为低NPAR组和高NPAR组,比较住院时长及并发症发生情况。结果:SMPP组的年龄、住院时长及呼吸音减低发生率均高于NSMPP组,实验室指标中,N%、CRP、NPAR、ALT、D-二聚体、LDH、PCT在重症组显著升高,而L%、白蛋白水平显著降低(均P < 0.05)。多因素Logistic回归分析显示,年龄、呼吸音减低、CRP、D-二聚体及LDH为SMPP的独立危险因素;在不纳入CRP的模型中,NPAR为SMPP的显著危险因素。ROC分析显示,模型一(CRP + NPAR + 协变量)与模型三(CRP + 协变量)AUC差异无统计学意义(DeLong检验P = 0.259)。与低NPAR组相比,高NPAR组患儿住院时间更长,胸腔积液和塑形支气管炎发生率更高(均P < 0.05),肺栓塞发生率差异无统计学意义。结论:NPAR水平与儿童肺炎支原体肺炎的严重程度及部分并发症密切相关,其对以CRP为核心模型的增量预测价值有限,但可作为常规炎症指标的有益补充,用于评估MPP患儿病情严重程度及并发症风险。
Abstract: Objective: To explore the association between the neutrophil percentage to albumin ratio (NPAR) and the severity and complications of Mycoplasma pneumoniae pneumonia (MPP) in children, and to evaluate its clinical utility. Methods: Retrospective cohort study. The clinical data of MPP children hospitalized in the Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University from January 2023 to June 2024 were collected. According to disease severity, patients were divided into a severe group (SMPP, n = 82) and a non-severe group (NSMPP, n = 208). Clinical characteristics and laboratory parameters were compared between the two groups. Multivariate Logistic regression methods were used to identify the influencing factors of SMPP. Models including and excluding CRP were established to assess the independent effect of NPAR. Patients were further stratified into low-NPAR and high-NPAR groups according to the median NPAR, and the associations with length of hospital stay and complications were analyzed. Results: Compared with the NSMPP group, the SMPP group showed significantly older age, a longer length of hospital stay, and a higher rate of decreased breath sounds. In laboratory findings, N%, CRP, NPAR, ALT, D-dimer, LDH, and PCT were all elevated in the SMPP group, whereas L% and albumin were reduced (all P < 0.05). Multivariable logistic regression showed that age, decreased breath sounds, CRP, D-dimer, and LDH were independent risk factors for SMPP; in the model excluding CRP, NPAR was an independent risk factor for SMPP. ROC analysis indicated no significant difference in AUC between the model including NPAR (CRP + NPAR + covariates) and the model without NPAR (CRP + covariates) (DeLong test, P = 0.259). Compared with the low-NPAR group, the high-NPAR group had a longer hospital stay and higher incidences of pleural effusion and plastic bronchitis (all P < 0.05), while there was no significant difference in the incidence of pulmonary embolism between groups. Conclusions: NPAR is closely associated with disease severity and selected complications in children with MPP. Although its incremental predictive value beyond a CRP-based model appears limited, NPAR may serve as a useful adjunct to routine inflammatory markers for risk stratification of SMPP and complications.
文章引用:邓玉欢, 丁圣刚. 中性粒细胞百分比与白蛋白比值(NPAR)在儿童肺炎支原体肺炎严重程度及并发症的价值[J]. 临床医学进展, 2026, 16(3): 834-842. https://doi.org/10.12677/acm.2026.163854

1. 引言

肺炎支原体(mycoplasma pneumoniae, MP)是儿童社区获得性肺炎中常见的病原体之一,可引起支气管炎、肺炎等多种呼吸道感染。多数患儿病情较轻,但部分病例可进展为重症肺炎支原体肺炎(severe mycoplasma pneumoniae pneumonia, SMPP),表现为持续高热、肺部影像学快速进展,并可伴发塑形性支气管炎、胸腔积液、肺栓塞等肺内或肺外并发症,导致住院时间延长、治疗复杂度增加,甚至影响远期肺功能[1] [2]。因此,寻找可用于早期识别重症及评估并发症风险的指标,对改善患儿预后具有重要意义。

中性粒细胞是机体固有免疫反应的重要效应细胞,在感染和炎症过程中发挥关键作用。既往有研究证明,中性粒细胞介导的免疫反应可能参与SMPP的发生发展[3] [4]。在急性炎症状态下机体常处于高代谢和应激状态,白蛋白作为负性急性期反应蛋白,其水平可反映炎症应激程度,并被报道与疾病严重程度相关[5] [6]。近年来提出的中性粒细胞百分比与白蛋白比值(neutrophil percentage-to-albumin ratio, NPAR)可综合反映炎症活化及机体应激消耗,已有研究报道其在多种感染性疾病及炎症相关疾病的风险评估及预后中具有一定价值[7]-[11]。然而,关于NPAR在肺炎支原体的重症识别及并发症风险评估方面的研究仍较为有限。

因此,本研究通过回顾性分析肺炎支原体肺炎患儿的临床资料,探讨NPAR与肺炎支原体肺炎严重程度及肺内并发症之间的关系,并进一步评估其在SMPP早期风险评估中的潜在价值,以期为临床识别高风险患儿提供简便、可行的参考指标。

2. 资料与方法

2.1. 临床资料

2.1.1. 研究对象

本研究是一项回顾性研究。选取2023年1月~2024年6月安徽医科大学第一附属医院儿科的肺炎支原体肺炎患儿进行研究。纳入标准:(1) 年龄为28天日龄以上,18岁以下的住院患儿;(2) 入院时存在肺炎的典型临床表现及影像学表现,包括发热、咳嗽、呼吸音异常及胸部影像学的浸润;(3) 通过咽拭子、或肺泡灌洗液标本核酸扩增检测检测到的MP DNA或RNA阳性。排除标准:(1) 既往反复呼吸道感染、患有先天性支气管肺发育不良、哮喘、肺结核等呼吸系统疾病者;(2) 存在先天性疾病、原发性或继发性免疫缺陷病、严重血液系统疾病及其余严重心、脑、肝、肾基础疾病患儿者;(3) 存在合并其他病原体感染的证据者;(4) 自动出院中断治疗及临床资料不完整者。

本研究获得安徽医科大学附属第一医院伦理委员会批准(批准文号:PJ2024-04-50)。

2.1.2. 资料收集

通过电子病历系统收集患者的人口统计学特征、住院时长、临床症状及体征、影像学以及所有患者入院后24小时内实验室检查结果,实验室检查结果包括血白细胞计数(white blood cell count, WBC)、N%、L%、C反应蛋白(C-reactive protein, CRP)、降钙素原(procalcitonin, PCT)、白蛋白、D-二聚体(D-dimer,D-D)等指标检测结果,并计算中性粒细胞百分比与白蛋白比值(NPAR)。

2.2. 研究分组

依据《儿童社区获得性肺炎管理指南(2024修订)》中关于重症肺炎的标准[12],将患儿分为重症肺炎支原体肺炎(severe mycoplasma pneumoniae pneumonia, SMPP)组和非重症肺炎支原体肺炎(non-severe mycoplasma pneumoniae pneumonia, NSMPP)组。

以队列中NPAR的中位数(1.47)为界,分为低NPAR组和高NPAR组,以评估两组之间临床结局的差异。

2.3. 统计学方法

采用SPSS 27.0进行统计学分析。首先对计量资料进行正态性检验,所有变量数据均为非正态分布,使用中位数(四分位间距) [M (P25, P75)]表示,组间比较采用Mann-Whitney U检验。对于计数资料以例数和百分比表示,组间比较采用卡方检验或Fisher精确检验。采用Logistic回归分析SMPP发生的影响因素。采用ROC曲线计算AUC及95%CI,采用DeLong检验(R软件pROC包)分析AUC间的差异。P < 0.05被认为差异有统计学意义。

3. 结果

3.1. 临床特征

本实验共纳入支原体肺炎的患儿290例,其中重症型82例,普通型208例。两组间性别分布上无统计学差异(P = 0.506)。与普通组相比,重症组患儿的年龄更大,住院时长更长、呼吸音减低发生率更高(均P < 0.05)。两组患儿的过敏史及湿啰音发生率方面的差异均未观察到统计学意义(所有P > 0.05)。见表1

3.2. 实验室检查

与NSMPP组相比,SMPP组的N%、CRP、NPAR、ALT、D-D、LDH、PCT均显著升高,而L%、Alb显著降低,差异具有统计学意义(均P < 0.05)。见表1

Table 1. Comparison of clinical characteristics and laboratory parameters between the SMPP group and the NSMPP group

1. SMPP组与NSMPP组临床特征及实验室指标比较

MPP (n = 290)

NSMPP (n = 208)

SMPP (n = 82)

P值

男(例,%)

154 (53.1%)

113 (54.3%)

41 (50%)

0.506

年龄(岁)

7 (5, 8)

6 (4, 8)

7 (5, 9)

0.008

住院时长(天)

5 (4, 7)

5 (4, 6)

7 (5, 8)

<0.001

湿啰音(例,%)

131 (45.2%)

93 (44.7%)

38 (46.3%)

0.802

呼吸音减低(例,%)

26 (9.0%)

7 (3.4%)

19 (23.2%)

<0.001

过敏史(例,%)

99 (34.1%)

75 (36.1%)

24 (29.3%)

0.272

WBC (*109/L)

6.7 (5.4, 8.6)

6.7 (5.3, 8.6)

7.1 (6.0, 9.1)

0.132

N%

62.2 (54.4, 68.9)

60.6 (52.6, 66.3)

65.8 (59.7, 74.5)

<0.001

L%

29.1 (22.6, 36.1)

30.8 (25.2, 38.9)

22.7 (17.5, 31.1)

<0.001

Hb (g/L)

125.5 (119.0, 131.3)

126.0 (120.0, 132.0)

123.5 (117.5, 131.0)

0.192

PLT (*109/L)

309.5 (243.0, 372.5)

311.5 (243.0, 385.0)

300.5 (234.3, 359.3)

0.331

CRP (mg/L)

12.14 (4.80, 22.71)

10.47 (4.00, 17.67)

23.01 (10.08, 42.90)

<0.001

总蛋白(g/L)

67.4 (64.4, 72.0)

68.3 (64.9, 71.7)

67.3 (62.8, 72.1)

0.122

白蛋白(g/L)

42.1 (40.0, 43.7)

42.2 (40.4, 44.0)

41.2 (37.6, 43.2)

0.002

NPAR

1.47 (1.27, 1.66)

1.44 (1.22, 1.59)

1.62 (1.41, 1.92)

<0.001

ALT (u/L)

16.0 (12.0, 21.0)

15.0 (12.0, 20.0)

17.0 (13.8, 27.0)

0.019

AST (u/L)

28.0 (23.0, 35.0)

28.0 (23.0, 34.0)

28.0 (23.0, 38.5)

0.344

D-D (μg/ml)

0.81 (0.51, 1.25)

0.74 (0.49, 1.02)

1.22 (0.62, 2.11)

<0.001

FIB (g/L)

4.55 (3.98, 5.06)

4.54 (3.98, 5.01)

4.61 (4.03, 5.19)

0.439

CK (u/L)

75.0 (53.8, 110.3)

75.0 (53.3, 108.0)

80.0 (54.3, 124.0)

0.716

CK-MB (u/L)

21.0 (17.0, 26.0)

21.0 (18.0, 26.0)

20.0 (16.0, 26.0)

0.223

LDH (u/L)

313.5 (273.0, 361.3)

307.0 (267.3, 348.8)

344.5 (283.8, 492.0)

<0.001

PCT (ng/ml)

0.07 (0.025, 0.12)

0.07 (0.025, 0.11)

0.07 (0.05, 0.18)

0.019

注:P值为SMPP组与NSMPP组比较所得;SMPP:重症肺炎支原体肺炎;NSMPP:非重症肺炎支原体肺炎;WBC:白细胞计数;N%:中性粒细胞百分比:L%:淋巴细胞百分比;Hb:血红蛋白;PLT:血小板计数;CRP:C反应蛋白;NPAR:中性粒细胞百分比与白蛋白比值;ALT:丙氨酸转氨酶;AST:天冬氨酸氨基转移酶;D-D:D-二聚体;FIB:纤维蛋白原;CK:肌酸激酶;CK-MB:肌酸激酶同工酶;LDH:乳酸脱氢酶;PCT:降钙素原(The P-value was obtained by comparing the SMPP group with the NSMPP group. SMPP: severe mycoplasma pneumoniae pneumonia; NSMPP: non-severe mycoplasma pneumoniae pneumonia; WBC: white blood cell count; N%: neutrophil percentage: L%: lymphocyte percentage; Hb: hemoglobin; PLT: platelet count; CRP: C-reactive protein; NPAR: neutrophil percentage-to-albumin ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase; D-D: D-dimer; FIB: fibrinogen; CK: creatine kinase; CK-MB: creatine kinase isoenzyme; LDH: lactate dehydrogenase; PCT: procalcitonin)。

3.3. SMPP的Logistic回归分析

在组间比较中,年龄、住院时长、呼吸音减低的发生、L%、N%、CRP、NPAR、ALT、Alb、D-D、LDH、PCT与病情严重程度显著相关。其中,N%和ALB参与NPAR计算,L%与NPAR之间存在强负相关(ρ = −0.905, P < 0.001),住院时长受疾病严重程度的影响,上述指标未纳入多因素logistic回归模型。此外,为评估NPAR的增量预测价值,构建嵌套模型进行比较:模型一纳入年龄、呼吸音减低、NPAR、ALT、D-D、LDH、PCT、CRP;模型二在模型一的基础上排除CRP;模型三在模型一的基础上排除NPAR。所有纳入多因素Logistic回归模型的自变量均进行了多重共线性诊断,方差膨胀因子(VIF)均<5,未见明显共线性。

结果显示,在模型一中,NPAR无统计学意义,年龄、呼吸音减低、D二聚体、LDH、CRP为SMPP的独立危险因素。在模型二中去除CRP后,NPAR成为显著的危险因素(OR = 5.649, 95%CI: 1.728~18.472, P = 0.004),年龄、呼吸音减低、D二聚体、LDH仍保持其独立预测价值。在模型三中,年龄、呼吸音减低、D-二聚体、LDH及CRP仍为SMPP发生的独立危险因素(P < 0.05)。见表2

Table 2. The logistic regression analysis of SMPP

2. SMPP的Logistic回归

模型一

模型二

模型三

OR (95%CI)

P值

OR (95%CI)

P值

OR (95%CI)

P值

年龄

1.215 (1.058~1.394)

0.006

1.216 (1.070~1.381)

0.003

1.234 (1.079~1.411)

0.002

呼吸音减低(1 = 有)

6.786 (2.158~21.337)

0.001

6.806 (2.343~19.768)

<0.001

6.733 (2.167~20.916)

<0.001

NPAR

2.069 (0.574~7.455)

0.266

5.649 (1.728~18.472)

0.004

-

-

ALT

0.983 (0.960~1.007)

0.173

0.983 (0.963~1.003)

0.094

0.984 (0.959~1.008)

0.193

D-D

1.497 (1.042~2.151)

0.029

1.442 (1.029~2.021)

0.033

1.546 (1.079~2.216)

0.018

LDH

1.006 (1.002~1.011)

0.007

1.006 (1.002~1.010)

0.006

1.007 (1.003~1.011)

0.002

PCT

1.039 (0.021~51.871)

0.985

5.072 (0.188~136.899)

0.334

0.883 (0.018~42.557)

0.95

CRP

1.060 (1.035~1.086)

<0.001

-

-

1.064 (1.040~1.089)

<0.001

注:-:该项不存在(-:no data)。

3.4. 不同多因素模型预测SMPP的效能比较

ROC曲线分析结果显示,不同多因素模型均具有较好的鉴别能力(见图1)。其中,模型一(CRP + NPAR + 协变量)的AUC为0.834,模型二(NPAR + 协变量,不含CRP)的AUC为0.805,模型三(CRP + 协变量,不含NPAR)的AUC为0.829。DeLong检验显示,模型一与模型三的AUC差异无统计学意义(Z = 1.129, P = 0.259) (见表3)。

Table 3. Predictive performance of different multivariable models for SMPP

3. 不同多因素模型预测SMPP的效能比较

组成

AUC (95%CI)

DeLong Z值

DeLong P值

模型一

CRP + NPAR + 协变量

0.834 (0.777~0.891)

1.129

0.259

模型二

NPAR + 协变量(不含CRP)

0.805 (0.747~0.863)

模型三

CRP + 协变量(不含NPAR)

0.829 (0.772~0.887)

注:采用DeLong检验比较模型一与模型三的AUC差异(The difference in AUC between Model 1 and Model 3 was assessed using the DeLong test)。

Figure 1. ROC curves of different multivariable models for SMPP

1. 不同多因素模型预测SMPP的ROC曲线

3.5. NPAR与其他单一指标预测SMPP效能的比较

NPAR与其他单一指标的比较结果见表4。DeLong检验显示,NPAR的预测效能与N%、D-二聚体、LDH及CRP相比差异均无统计学意义(均P > 0.05)。

Table 4. Comparison of the predictive performance of NPAR with other individual indicators for SMPP

4. NPAR与其他单一指标预测SMPP效能的比较

比较

AUC1 (NPAR)

AUC2 (比较指标)

ΔAUC (AUC1~AUC2)

Z值

P值(双侧)

NPAR vs N%

0.707

0.698

0.009

0.561

0.575

NPAR vs DD

0.707

0.682

0.025

0.605

0.545

NPAR vs LDH

0.707

0.643

0.064

1.605

0.109

NPAR vs CRP

0.707

0.722

−0.015

−0.394

0.694

注:采用DeLong检验进行比较AUC差异。

3.6. 不同NPAR分组与住院时长及并发症发生情况比较

Table 5. Comparison of length of hospital stay and complications between NPAR groups

5. 不同NPAR分组与住院时长及并发症发生情况比较

低NPAR

高NPAR

P值

住院时长(天)

5 (4, 6)

6 (5, 9)

<0.001

胸腔积液(%)

10 (6.9%)

21 (14.4%)

0.04

塑形支气管炎(%)

0 (0%)

9 (3.1%)

0.003

肺栓塞(%)

0 (0%)

1 (0.3%)

1

注:NPAR:中性粒细胞百分比与白蛋白的比值(NPAR:neutrophil percentage-to-albumin ratio)。

高NPAR组住院时长显著高于低NPAR组(P < 0.001)。在并发症方面,高NPAR组的胸腔积液(P = 0.04)、塑形支气管炎(P = 0.003)的发生率显著高于低NPAR组。本研究共观察到1例肺栓塞,发生于高NPAR组。见表5

4. 讨论

本研究通过回顾性分析2023年1月至2024年6月我院收治的MPP患儿,评估了中性粒细胞百分比与白蛋白比值在儿童MPP严重程度及并发症预测中的价值。在290例MPP患儿中,有82例为SMPP,9例发生了塑形支气管炎,31例发生了胸腔积液,1例发生了肺栓塞。结果显示,重症组支原体肺炎患儿NPAR水平显著高于普通组患儿。此外,高NPAR组患儿住院时间更长,且胸腔积液、塑形支气管炎的发生率更高,这提示NPAR与MPP严重程度相关,也可能与炎症渗出倾向及重症相关并发症发生风险相关。

重症肺炎支原体感染的发生与宿主免疫反应的强度及调控失衡相关。中性粒细胞作为固有免疫系统的重要效应细胞,在感染相关炎症中具有双重作用,既参与病原的清除,在过度激活时也可通过活性氧(ROS)生成、脱颗粒释放蛋白酶、炎性介质释放及中性粒细胞外陷阱(NETosis)等途径造成炎症放大并介导组织损伤[13] [14]。通过对支原体感染患儿的肺泡灌洗液进行测序发现,SMPP患儿的固有免疫反应显著增强,中性粒细胞趋化、脱颗粒及相关信号通路激活更明显[4]。另外,有研究表示免疫抑制可能会减轻支原体感染所致肺损伤[15]。在MP感染的动物实验模型中也证实,中性粒细胞浸润可加重肺损伤[3]。与上述证据一致,本研究中NPAR升高与重症及并发症的发生呈正相关,提示中性粒细胞驱动的炎症放大效应可能参与病情重症化及组织损伤过程。

白蛋白作为一种负性急性期反应蛋白,其在急性炎症状态下常显著下降。既往研究表明,在感染及炎症应激过程中,炎性细胞因子可抑制肝脏对白蛋白的合成,同时介导血管通透性增加导致白蛋白外渗及分解加速,进而使血清白蛋白水平明显下降[6] [16]。此外,白蛋白在维持血管内皮屏障稳定、抗氧化及免疫调控中发挥一定作用,其降低可能不利于机体的抗感染与修复能力发挥作用,从而加重组织损伤[17] [18]。因此,NPAR作为中性粒细胞比例与白蛋白的比值,可能比单一指标更能反映炎症激活与屏障/营养状态改变的综合病理生理状态,为临床早期识别重症倾向及并发症风险提供线索。

在多因素模型分析中,本研究发现年龄、呼吸音减低、C反应蛋白(CRP)、D-二聚体及乳酸脱氢酶(LDH)均为SMPP的独立危险因素。上述结果与既往研究一致,反映了SMPP以免疫炎症反应过度激活为主要特征[19]。值得注意的是,NPAR在纳入CRP的模型中未表现为独立危险因素,而在排除CRP后其独立效应增强(OR = 5.649)。结合模型比较结果(模型一AUC = 0.834 vs模型三AUC = 0.829,DeLong检验P = 0.259),提示NPAR对以CRP为核心的多因素模型增量预测价值有限。同时,单一指标进行DeLong检验结果显示,NPAR的AUC并未显著优于CRP或N%,与D-二聚体、LDH相比亦未达到统计学差异。上述结果提示,NPAR不应被视为优于CRP或N%的替代指标,其作为单一指标预测SMPP效能方面的优势有限。这种现象可能与NPAR与CRP在反映炎症反应方面存在信息重叠有关。CRP作为急性期正相反应蛋白,是炎症级联反应激活后产生的下游产物[20],而NPAR由中性粒细胞比例和白蛋白水平构成,其中两者均受炎症反应影响[6]。当CRP纳入模型后,其可能优先解释与疾病严重程度相关的炎症信号,从而在统计学上削弱NPAR的独立效应;而在不包含CRP的模型中,NPAR作为复合指标仍可提供一定的风险分层信息。NPAR可作为传统炎症指标的补充,用于辅助识别重症倾向。

此外,在并发症方面,本研究观察到高 NPAR 组患儿胸腔积液和塑形支气管炎发生风险显著升高,提示 NPAR不仅与肺炎支原体肺炎严重程度相关,也与并发症的发生密切相关。既往研究表明,在合并胸腔积液的肺炎支原体肺炎中,胸腔积液中支原体核酸阳性患儿外周血中性粒细胞比例,CRP,LDH及D-二聚体水平均显著升高,且住院时间明显延长,提示胸腔积液伴随着更强的全身炎症反应[21]。在本研究中,高NPAR组胸腔积液发生率明显升高,提示NPAR可能帮助识别具有更强系统炎症反应与渗出倾向的高风险人群。塑形支气管炎是重症支原体肺炎的严重并发症,其发生与中性粒细胞驱动的强烈局部炎症反应密切相关[22]。也有研究发现血清白蛋白下降是支原体肺炎反复发生塑形支气管炎的独立危险因素之一[23],提示低蛋白代表着持续炎症状态及屏障受损在塑形支气管炎的发生与迁延过程中可能发挥重要作用。本研究中的塑形支气管炎仅发生于高NPAR组,进一步支持NPAR与炎症并发症的相关性。高NPAR反映的是以中性粒细胞升高和白蛋白降低为特征的机体状态,提示存在显著的炎症应激和血管通透性改变,这种状态可能增加炎症相关并发症的发生风险,并与病程迁延或并发症反复发生相关。需要指出的是,我们研究中仅有1例肺栓塞,其发生于高NPAR组,提示高NPAR人群可能存在高凝风险,未来需扩大样本进一步评估。

综上所述,NPAR水平与儿童肺炎支原体肺炎的严重程度及相关并发症密切相关,在CRP等传统炎症指标基础上具有一定补充价值,在SMPP的识别和并发症风险评估有一定意义。本研究亦存在若干局限性。首先,这是一项单中心回顾性研究,可能存在选择偏倚。其次,某些并发症的例数较少,可能影响统计效力。未来仍需前瞻性、多中心的大样本研究验证其预测价值。

基金项目

人口健康领域安徽省重点研究和开发计划(201904a07020042)。

NOTES

*通讯作者。

参考文献

[1] Waites, K.B. and Talkington, D.F. (2004) Mycoplasma pneumoniae and Its Role as a Human Pathogen. Clinical Microbiology Reviews, 17, 697-728. [Google Scholar] [CrossRef] [PubMed]
[2] Waites, K.B., Xiao, L., Liu, Y., Balish, M.F. and Atkinson, T.P. (2017) Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clinical Microbiology Reviews, 30, 747-809. [Google Scholar] [CrossRef] [PubMed]
[3] Tamiya, S., Yoshikawa, E., Ogura, M., Kuroda, E., Suzuki, K. and Yoshioka, Y. (2021) Neutrophil-Mediated Lung Injury Both via TLR2-Dependent Production of IL-1α and IL-12 P40, and TLR2-Independent CARDS Toxin after Mycoplasma pneumoniae Infection in Mice. Microbiology Spectrum, 9, e0158821. [Google Scholar] [CrossRef] [PubMed]
[4] Zhu, Y., Luo, Y., Li, L., Jiang, X., Du, Y., Wang, J., et al. (2023) Immune Response Plays a Role in Mycoplasma pneumoniae Pneumonia. Frontiers in Immunology, 14, Article 1189647. [Google Scholar] [CrossRef] [PubMed]
[5] Eckart, A., Struja, T., Kutz, A., Baumgartner, A., Baumgartner, T., Zurfluh, S., et al. (2020) Relationship of Nutritional Status, Inflammation, and Serum Albumin Levels during Acute Illness: A Prospective Study. The American Journal of Medicine, 133, 713-722.e7. [Google Scholar] [CrossRef] [PubMed]
[6] Wiedermann, C.J. (2021) Hypoalbuminemia as Surrogate and Culprit of Infections. International Journal of Molecular Sciences, 22, Article 4496. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, C., Yu, X., Wang, T., Ding, M., Ran, L., Wang, L., et al. (2023) Association between Neutrophil Percentage-to-Albumin Ratio and Pneumonia in Patients with Traumatic Spinal Cord Injury. Spinal Cord, 61, 106-110. [Google Scholar] [CrossRef] [PubMed]
[8] Mousa, N., salah, M., Elbaz, S., Elmetwalli, A., Elhammady, A., Abdelkader, E., et al. (2024) Neutrophil Percentage-to-Albumin Ratio Is a New Diagnostic Marker for Spontaneous Bacterial Peritonitis: A Prospective Multicenter Study. Gut Pathogens, 16, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[9] Gul, S., Uysal, M.A., Yeter, A., Eren, R., Demirkol, B. and Niksarlıoglu, E.Y.O. (2025) The Clinical Usefulness of Neutrophil Percentage/Albumin Ratio in Predicting the One-Month Mortality in Chronic Obstructive Pulmonary Disease Patients Hospitalized with Community-Acquired Pneumonia. BMC Pulmonary Medicine, 25, Article No. 288. [Google Scholar] [CrossRef] [PubMed]
[10] Lv, X.N., Shen, Y.Q., Li, Z.Q., et al. (2023) Neutrophil Percentage to Albumin Ratio Is Associated with Stroke-Associated Pneumonia and Poor Outcome in Patients with Spontaneous Intracerebral Hemorrhage. Frontiers in Immunology, 14, Article 1173718. [Google Scholar] [CrossRef] [PubMed]
[11] Deng, L., Wang, T., Duan, Y., Liu, B., Jiang, J., Liu, D., et al. (2024) Neutrophil Percentage-to-Albumin Ratio Is a Potential Marker of Intravenous Immunoglobulin Resistance in Kawasaki Disease. Scientific Reports, 14, Article No. 15232. [Google Scholar] [CrossRef] [PubMed]
[12] 中华医学会儿科学分会呼吸学组, 中华儿科杂志编辑委员会, 中国医药教育协会儿科专业委员会. 儿童社区获得性肺炎管理指南(2024修订) [J]. 中华儿科杂志, 2024, 62(10): 920-930.
[13] Porto, B.N. and Stein, R.T. (2016) Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing? Frontiers in Immunology, 7, Article 311. [Google Scholar] [CrossRef] [PubMed]
[14] Aroca-Crevillén, A., Vicanolo, T., Ovadia, S. and Hidalgo, A. (2024) Neutrophils in Physiology and Pathology. Annual Review of Pathology: Mechanisms of Disease, 19, 227-259. [Google Scholar] [CrossRef] [PubMed]
[15] Shi, S., Zhang, X., Zhou, Y., Tang, H., Zhao, D. and Liu, F. (2019) Immunosuppression Reduces Lung Injury Caused by Mycoplasma Pneumoniae Infection. Scientific Reports, 9, Article No. 7147. [Google Scholar] [CrossRef] [PubMed]
[16] Gremese, E., Bruno, D., Varriano, V., Perniola, S., Petricca, L. and Ferraccioli, G. (2023) Serum Albumin Levels: A Biomarker to Be Repurposed in Different Disease Settings in Clinical Practice. Journal of Clinical Medicine, 12, Article 6017. [Google Scholar] [CrossRef] [PubMed]
[17] Shang, D., Peng, T., Gou, S., Li, Y., Wu, H., Wang, C., et al. (2016) High Mobility Group Box Protein 1 Boosts Endothelial Albumin Transcytosis through the Rage/Src/Caveolin-1 Pathway. Scientific Reports, 6, Article No. 32180. [Google Scholar] [CrossRef] [PubMed]
[18] Bein, K., Birru, R.L., Wells, H., Larkin, T.P., Cantrell, P.S., Fagerburg, M.V., et al. (2020) Albumin Protects Lung Cells against Acrolein Cytotoxicity and Acrolein-Adducted Albumin Increases Heme Oxygenase 1 Transcripts. Chemical Research in Toxicology, 33, 1969-1979. [Google Scholar] [CrossRef] [PubMed]
[19] Zhang, Z., Dou, H., Tu, P., Shi, D., Wei, R., Wan, R., et al. (2022) Serum Cytokine Profiling Reveals Different Immune Response Patterns during General and Severe Mycoplasma pneumoniae Pneumonia. Frontiers in Immunology, 13, Article 1088725. [Google Scholar] [CrossRef] [PubMed]
[20] Gabay, C. and Kushner, I. (1999) Acute-Phase Proteins and Other Systemic Responses to Inflammation. New England Journal of Medicine, 340, 448-454. [Google Scholar] [CrossRef] [PubMed]
[21] Li, S., Zhou, J., He, J., Yang, D., Zhu, G., Tang, L., et al. (2024) Clinical Profiles of Mycoplasma pneumoniae Pneumonia in Children with Different Pleural Effusion Patterns: A Retrospective Study. BMC Infectious Diseases, 24, Article No. 919. [Google Scholar] [CrossRef] [PubMed]
[22] Huang, X., Qin, H., Zhang, R., Jia, X., Zhao, D. and Liu, F. (2025) Neutrophils Are Involved in the Development and Outcomes of Plastic Bronchitis Associated with Mycoplasma pneumoniae Pneumonia. Respiratory Research, 26, Article No. 92. [Google Scholar] [CrossRef] [PubMed]
[23] 李万怡, 王舒颖, 王海珍, 等. 儿童肺炎支原体肺炎反复发生塑型性支气管炎的危险因素分析[J]. 中国当代儿科杂志, 27(10): 1220-1226.